Home Stock list Ultragenyx Reports Incentive Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Reports Incentive Grant Under Nasdaq Listing Rule 5635(c)(4)

0

NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on developing and commercializing novel therapies for rare and ultra-rare diseases, today announced the granting of non-qualified stock options to purchase a total of 20,480 ordinary shares of the company and 11,620 restricted shares of ordinary shares of the company to two newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under Ultragenyx’s employment incentive plan, with a grant date of May 1, 2022, as incentive materials for new employees entering employment at Ultragenyx as per Nasdaq. Registration Rule 5635(c)(4).

Restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, provided the employee is continuously employed by the company on those vesting dates. Stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting in respect of 1/48th of the underlying shares options on each monthly anniversary thereafter, subject to the employee being continuously employed by the Company on such vesting dates. The stock options have a term of ten years and an exercise price of $70.69 per share, equal to the closing price per share of Ultragenyx common stock on April 29, 2022.

About Ultranyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to providing patients with new products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at treating diseases with high unmet medical needs and clear biology for treatment, for which there are generally no approved therapies that address the underlying disease. underlying.

The company is led by a management team experienced in the development and commercialization of therapies for rare diseases. Ultragenyx’s strategy is based on time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients in the shortest possible time.

For more information about Ultragenyx, please visit the company’s website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370